Long-term observation of BHC001 treatment for beta thalassemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study observes the long-term safety and efficacy of BHC001 in patients with transfusion-dependent beta thalassemia (TDT). Participants who have been treated with BRL-101 will be monitored for delayed safety risks, including the emergence of neoplasms and hematological disorders. The study aims to gather comprehensive data on the long-term effects of the treatment following intravenous infusion. It is an observational study, meaning it will focus on collecting data without any experimental intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
2. Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.

Exclusion Criteria:

\- There are no exclusion criteria for this study

Where it's running

• The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
  Nanning, Guangxi, China Recruiting
• Xiangya Hospital of Central South University
  Changsha, Hunan, China Recruiting

Study contacts

• Study coordinator: Xiaochen Wang, PhD
• Email: xcwang@brlmed.com
• Phone: 021-64340008

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term safety and effectiveness of BRL-101 in transfusion-dependent beta-thalassemia

  This study looks at whether BRL-101 remains safe and effective over the long term for people with transfusion-dependent beta-thalassemia.

  Recruiting at 3 sites Bioray Laboratories · Guangzhou, Guangdong and 6 other locations · NCT06298630

• Investigating genetic factors in blood disorders

  This study is trying to find out how genes affect blood disorders like sickle cell disease and thalassemia by looking at the DNA of many people with these conditions.

  Recruiting at 17 sites Cyprus Institute of Neurology and Genetics · Boston, Massachusetts and 25 other locations · NCT05799118

• Immune suppression treatment for sickle cell disease and beta-thalassemia patients receiving stem cell transplants

  This study is testing if a new immune suppression treatment can help people with sickle cell disease or beta-thalassemia have better outcomes when they receive stem cell transplants.

  Recruiting at 6 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 5 other locations · NCT05736419

• Combining Thalidomide with Danazol and Prednisolone for difficult beta-thalassemia in children

  This trial tests whether adding danazol and prednisolone to thalidomide helps children with transfusion-dependent beta-thalassemia who did not respond to thalidomide alone.

  Recruiting Phase 3 Khyber Medical University Peshawar · Peshawar, Khyber Pakhtunkhwa · NCT07884773

• Partial stem cell transplant for sickle cell disease and beta-thalassemia using matched donors

  This study tests a partial stem cell transplant from matched donors to help people with severe sickle cell disease or beta-thalassemia see if more donor cells can persist long-term.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07599176

• Testing 9MW3011 for patients with non-transfusion-dependent beta-thalassemia

  This study is testing a new drug called 9MW3011 to see if it is safe and effective for people with non-transfusion-dependent beta-thalassemia.

  Recruiting at 2 sites Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Nanning, Guangxi and 1 other locations · NCT06772766

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.